Dan Pettitt
10 Papers
233 Citations
Dan Pettitt is an academic researcher. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 9, co-authored 9 publications.
Chat about Author
Papers
•Journal Article
High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population.
Joe V. Selby,Tiffany Peng,Andrew J. Karter,Mark E. Alexander,Stephen Sidney,Jean Lian,Amy Arnold,Dan Pettitt +7 more
TL;DR: HT, DL, and DM co-occur in most affected individuals and to avoid fragmentation of care, disease management strategies should aim to manage these conditions within the same programs.
100
•Journal Article
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
TL;DR: Patients starting a new COX-2 specific inhibitor had a greater lifetime history of adverse reactions of all kinds, but particularly gastrointestinal adverse drug reactions, and had more severe scores for pain, functional disability, fatigue, helplessness, and global severity.
73
•Journal Article
Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy
TL;DR: PI use, but not other GI drug use, is a marker for increased susceptibility to ulcers among NSAID users, and this risk of upper GI ulcers is increased in PPI users regardless of which NSAID is used (nonselective or COX-2-specific inhibitor).
70
•Journal Article
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
TL;DR: Rofecoxib, but not celecoxib and NS NSAID, is associated with an increased risk of edema and blood pressure increase compared to nonusers of NSAID.
60
Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy?
Shuchita Agarwal,Simon S K Tang,Noah Rosenberg,Dan Pettitt,Trent McLaughlin,Amie T. Joyce,J. Sanford Schwartz +6 more
TL;DR: Patients initiating AH before LL therapy, or LL before AH therapy, were less likely to be adherent than patients prescribed both agents simultaneously (odds ratios = 0.838 and 0.691, respectively; P < 0.0001).
36